Rats were divided into three groups:
sham, 6h-ischemia, and KDZ treatment (KDZ). The neurological deficits were determined by the Garcia score. The
cerebral infarct volume was measured by
2,3,5-triphenyltetrazolium chloride (TTC) staining, and brain water content was also evaluated. Serum
creatinine kinase (CK),
lactate dehydrogenase (LDH), and
creatine kinase-myocardial band (CK-MB) activity, myocardial tissue
malondialdehyde (MDA) levels, L-
Glutathione (GSH) levels, and
superoxide dismutase (SOD) activity as well as mitochondrial
cytochrome c oxidase (COX) activity were determined. Mitochondrial COX I and COX III
mRNA expressions of myocardial tissues were measured by RT-PCR.
RESULTS: Impaired neurological function and
brain edema were observed in the 6h-ischemia group. TTC staining showed that the 6h-ischemia group had larger
infarct zones than the
sham group. Myocardial ischemic changes (widened myocardial cell gap, cracks, and obvious
edema) were detected in the 6h-ischemia group compared with the
sham group, with elevated serum CK-MB activity and CK and LDH levels. Electrocardiography showed lower medium frequency (MF) and high frequency (HF) in the 6h-ischemia group compared with the
sham group. In myocardial tissue, COX activity was elevated in the 6h-ischemia compared with the
sham group, while SOD, GSH, and MDA levels, and COX I and COX III
mRNA expressions remained unchanged. KDZ injection decreased neurological impairment,
brain edema, gaps between cells, and
infarct size. Compared with the 6h-ischemia group, it reduced serum CK-MB activity and CK and LDH levels, and MDA levels in myocardial tissue. KDZ significantly increased GSH levels, SOD activity, and mitochondria COX activity and the expression of COX I and COX III
mRNA in myocardial tissue compared with the
sham group.
CONCLUSION: